Astellas Pharma Inc.

Tokyo Stock Exchange:4503.T

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

Japan

Market Cap

USD 17.34 B

Share Price

USD 9.69

Avg Daily Volume

6,588,604

Change (1 day)

0.99%

Change (1 year)

-2.61%

Change (YTD)

-0.93%

Astellas Pharma Inc. Return on Capital Employed (ROCE) for the year ending March 31, 2025: 2.16%

Astellas Pharma Inc. Return on Capital Employed (ROCE) is 2.16% for the year ending March 31, 2025, a 31.46% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Astellas Pharma Inc. Return on Capital Employed (ROCE) for the year ending March 31, 2024 was 1.64%, a -78.91% change year over year.
Astellas Pharma Inc. Return on Capital Employed (ROCE) for the year ending March 31, 2023 was 7.79%, a -20.63% change year over year.
Astellas Pharma Inc. Return on Capital Employed (ROCE) for the year ending March 31, 2022 was 9.81%, a 12.04% change year over year.
Astellas Pharma Inc. Return on Capital Employed (ROCE) for the year ending March 31, 2021 was 8.75%, a -46.80% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Return on Capital Employed (ROCE)	Return on Equity (ROE)	Return on Assets (ROA)	Revenue Per Share

Tokyo Stock Exchange: 4503.T

Astellas Pharma Inc.

CEO	Mr. Naoki Okamura BSc
IPO Date	Jan. 4, 2000
Location	Japan
Headquarters	2-5-1, Nihonbashi-Honcho
Employees	14,754
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.